A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.
A new prescription discount card, SmartRx, a division of Smarty, joins GoodRx and SingleCare in the prescription discount card arena. SmartRx offers its users a free discount card and a paid membership program. The SmartRx Discount Card helps consumers save up to 80% on their prescription drugs. SmartRx+ is a monthly membership program that offers rebates for doctor or dentist visits, telehealth care, prescription glasses or contacts, annual vaccines, and pet medications.
Vipin Porwal
“An increase in healthcare costs over the past few years coupled with this past year’s inflation rates have really affected consumer’s bottom line. SmartRx is a smart healthcare cost saving solution that goes beyond prescription drug costs to help tackle these consumer concerns about health care costs,” Vipin Porwal, chief executive officer and founder of Smarty and SmartRx, told Formulary Watch.
SmartRx works with PBMs to pass on discounts when consumers present their SmartRx coupon or discount card at the pharmacy, Porwal said.
The membership rate for SmartyRx+ is $19 per month after a seven-day trial for $3. Users get a $15 cashback bonus rebate on their first prescription purchase, plus $30 annual rebate for vaccines, $50 a month for doctor and dental visits, $125 for annual for prescription glasses and contacts, $25 a month for pet medications, and other rebates.
In addition, the SmartRx Discount Card is accepted at more than 65,000 pharmacies nationwide.
In a recent SmartRx survey, 66% of respondents agreed or strongly agreed that prescriptions are too costly. Nearly half (48%) of respondents said they would use a subscription service that offers cashback and rebates on prescriptions.
Smarty is an online shopping destination that automatically applies the best coupon on purchases from more than 6,000 U.S. retailers and 1,500 global merchants.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More